Literature DB >> 11404389

Priming effects of substance P on calcium changes evoked by interleukin-8 in human neutrophils.

C Dianzani1, G Lombardi, M Collino, C Ferrara, M C Cassone, R Fantozzi.   

Abstract

The neurokinin (NK) substance P (SP), which is a mediator of neurogenic inflammation, has been reported to prime human polymorphonuclear neutrophils (PMNs). The priming effects of SP on PMNs activated by recombinant interleukin-8 (rIL-8) were investigated. SP enhanced, in a dose- and time-dependent way, the rise in cytosolic free-calcium concentration, [Ca(2+)]i, evoked by the chemokine. The priming effects of SP were abolished by exposing PMNs to a calcium-free medium supplemented with EGTA. The C-terminal peptides SP(4-11) and SP(6-11) but not the N-terminal peptide SP(1-7) shared the priming effects of SP. The selective NK-1 receptor agonist [Sar-9, MetO2-11]SP mimicked the effects of SP, which were not reproduced by the selective NK-2 receptor agonist [betaAla-8]-NKA(4-10) or the selective NK-3 agonist senktide. Two selective NK-1 antagonists, CP96,345 and L703,606, dose dependently inhibited SP priming effects. These results demonstrated that SP primes PMNs exposed to rIL-8 and suggested that SP priming effects are receptor mediated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404389

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  11 in total

Review 1.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells.

Authors:  Margherita Gallicchio; Arianna Carolina Rosa; Elisa Benetti; Massimo Collino; Chiara Dianzani; Roberto Fantozzi
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 3.  Crosstalk between the nociceptive and immune systems in host defence and disease.

Authors:  Stephen B McMahon; Federica La Russa; David L H Bennett
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

4.  Immobilized IL-8 Triggers Phagocytosis and Dynamic Changes in Membrane Microtopology in Human Neutrophils.

Authors:  Michael T Beste; Elena B Lomakina; Daniel A Hammer; Richard E Waugh
Journal:  Ann Biomed Eng       Date:  2015-01-13       Impact factor: 3.934

Review 5.  Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+.

Authors:  Tim D Werry; Graeme F Wilkinson; Gary B Willars
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

6.  Substance P increases neutrophil adhesion to human umbilical vein endothelial cells.

Authors:  Chiara Dianzani; Massimo Collino; Grazia Lombardi; Giovanni Garbarino; Roberto Fantozzi
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

7.  Acid-induced mesenteric hyperemia in rats: role of CGRP, substance P, prostaglandin, adenosine, and histamine.

Authors:  Felix W Leung; Fumihiro Iwata; Kyoji Seno; Joseph W C Leung
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

8.  Signaling and cross-talk by C5a and UDP in macrophages selectively use PLCbeta3 to regulate intracellular free calcium.

Authors:  Tamara I A Roach; Robert A Rebres; Iain D C Fraser; Dianne L Decamp; Keng-Mean Lin; Paul C Sternweis; Mel I Simon; William E Seaman
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

9.  Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).

Authors:  Irene Chernova; Jian-Ping Lai; Haiying Li; Lynnae Schwartz; Florin Tuluc; Helen M Korchak; Steven D Douglas; Laurie E Kilpatrick
Journal:  J Leukoc Biol       Date:  2008-10-03       Impact factor: 4.962

10.  Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes.

Authors:  M Gallicchio; E Benetti; A C Rosa; R Fantozzi
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.